Find early tests for Parkinson
- Trial ID
- NCT06846658
- Official Title
- Exploring the Olfactory Mucosa, Blood and Urine for the Identification of Early Biomarkers of Parkinson's Disease, Atypical Parkinsonisms and Neurocognitive Disorders Due to Lewy Body Disease
- Goal
- Find early tests for Parkinson
- Status
- RECRUITING
- Sponsor
- Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
- Study Type
- OBSERVATIONAL
- Enrollment
- 180 participants
- Conditions
- Parkinson Disease, MSA - Multiple System Atrophy, Lewy Body Dementia (LBD), Neurodegenerative Disease, Healthy Subjects (HS)
Summary For Families
The goal is to find early biological signs that can distinguish Parkinson's disease, atypical parkinsonisms like multiple system atrophy, and Lewy body dementia from each other and from healthy aging. Researchers collect samples from the olfactory mucosa (the smell-related nasal tissue), blood and urine, then analyze them for molecular biomarkers such as misfolded proteins like alpha-synuclein and other inflammatory or metabolic signatures that might appear early in disease. About 180 people are being enrolled, including adults with PD, MSA, DLB or other neurodegenerative movement disorders, plus healthy volunteers; the public listing does not specify an age limit.
Locations
- Consorzio Interuniversitario Risonanze Magnetiche Metallo Proteine (CIRMMP), Sesto Fiorentino, FI, Italy
- IRCCS Centro San Giovanni di Dio, Brescia, Italy
- Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy
Frequently Asked Questions
- What is this trial testing?
- This trial is studying an experimental treatment. The goal is to find early biological signs that can distinguish Parkinson's disease, atypical parkinsonisms like multiple system atrophy, and Lewy body dementia from each other and from healthy aging. Researchers collect samples from the olfactory mucosa (the smell-related nasal tissue), blood and urine, then analyze them for molecular biomarkers such as misfolded proteins like alpha-synuclein and other inflammatory or metabolic signatures that might appear early in disease. About 180 people are being enrolled, including adults with PD, MSA, DLB or other neurodegenerative movement disorders, plus healthy volunteers; the public listing does not specify an age limit.
- Who can participate?
- Eligibility criteria vary. Check the full listing on ClinicalTrials.gov for detailed inclusion and exclusion criteria.
- Where is this trial located?
- This trial is recruiting at 3 locations.
- Does it cost anything to join?
- No. There is no cost to participate. Study-related care and treatment are provided at no charge.
- How long does the trial last?
- This trial is estimated to last approximately 2 years and 6 months.
- Will I get the real drug or a placebo?
- It depends on the trial design. Some Parkinson's trials are placebo controlled, meaning a portion of participants get an inactive comparison while others get the experimental treatment. Some use crossover designs so everyone eventually receives the active treatment at some point. Observational trials do not use a placebo at all because they are not testing a new treatment. The consent form for any specific trial spells out the design and your odds of being assigned to placebo before you enroll.
- How often will I need to visit the study site?
- Visit frequency varies by trial. Many Parkinson's studies require an in person visit every 4 to 12 weeks during the active treatment phase, with shorter or longer gaps depending on the design. The site coordinator can give you the full visit schedule before you sign anything, so you know what the time commitment looks like.
- Can I leave the trial if I change my mind?
- Yes. You can withdraw from any clinical trial at any time, for any reason, without affecting your standard medical care. Trials are voluntary by law. The team may ask if you are willing to do a brief exit visit so they can collect safety information, but you are not obligated.
- Will travel or parking be reimbursed?
- Many trials reimburse for parking, mileage, and sometimes lodging if the site is far from your home. Reimbursement policies vary by sponsor and site. When you contact the trial team, ask specifically what is covered and how reimbursement is processed.
- Can my spouse or care partner come with me to visits?
- In most cases yes, and it is often encouraged. Care partners can help with notes, questions, and getting home safely after a long visit. Some study assessments do need to happen one on one, but care partners are usually welcome for the rest of the appointment.